Press Releases and News

With “the Company” or “VibroSense” is meant VibroSense Dynamics AB (publ) with registration number 556669–2223. Amounts in parentheses in this report refer to the corresponding period of the previous year. The Company previously applied a broken financial year until the last Annual General Meeting, at which it was decided to change the Company’s financial year from a broken fiscal year (1 July – 30 June) to a calendar year (1 January – 31 December). Therefore, the current financial year will cover a period of 18 months (6 quarters) and extend until 31 December 2025.

VibroSense Dynamics AB (publ) enters the autumn with a strengthened organisation, new patent advancements, and preparations for the launch of VibroSense Meter® II in China.

On September 1st, company co-founder Toni Speidel assumed the role of CEO. Simultaneously, the marketing and sales team was strengthened with the addition of two new Marketing & Sales Specialists. To further support the company’s expansion in China, a local Key Account Manager has also been appointed for the Chinese market.

VibroSense Dynamics AB (“VibroSense”) has received an Intention to Grant from the European Patent Office (EPO) regarding a patent on a Biomarker to predict the risk of developing permanent nerve damage after cancer treatment with chemotherapy.

The biomarker is expected to pave the way for reducing the degree of Chemotherapy-Induced Peripheral Neuropathy (CIPN), which is a common complication of cancer treatment with chemotherapy, especially in the treatment of breast, lung and colorectal cancer.

VibroSense Dynamics AB (publ) announces today that the company has received the official certificate from the Chinese pharmaceutical authority NMPA (National Medical Products Administration). The company had previously informed the market that the NMPA approval had been granted, and with the formal certificate in hand, the three-year commercial agreement with the exclusive Chinese partner UMCare now comes into effect.

The agreement, which has a total value of approximately EUR 3.74 million, covers the launch, marketing and sales of VibroSense products in the Chinese market.

VibroSense Dynamics AB (publ) has signed a research agreement with the renowned Diabetic Foot Unit at the Complutense University of Madrid. The purpose of the collaboration is to validate the VibroSense Meter® II in clinical practice and to objectively compare the technology with current standard methods used to diagnose diabetic neuropathy.

VibroSense Dynamics AB (publ) announces today that its medical device, VibroSense Meter® II, has been approved by the National Medical Products Administration (NMPA) in China.

VibroSense Dynamics AB has received a European patent on a principle that measures skin temperature automatically and wirelessly, before and during an examination, which ensures measurement quality. The patent is a so-called European patent (Unitary Patent) which has been extended by two additional countries.

VibroSense Dynamics AB has signed a distributor agreement with QST Technologies in Singapore and Hong Kong. The agreement allows QST Technologies to market and sell the VibroSense Meter® II in Singapore and Hong Kong within the product's application areas.

VibroSense Chinese distributor UMCARE has submitted a supplementary response to the Chinese regulatory authority NMPA. Provided that the NMPA approves the company's application, the regulatory approval is expected to be
 completed in April 2025.

VibroSense Dynamics AB has signed an agreement with LifeMed OY in Finland. The agreement allows LifeMed OY to market and sell VibroSense Meter II in Finland within the product's application areas.

“We are excited to have started this cooperation with LifeMed in the Finnish market. VibroSense Meter II has a wide range of applications and we look forward to offering our solutions in Finland together with LifeMed”, says Tarik Cengiz, CEO of VibroSense Dynamics AB.

Tarik Cengiz takes office today as the new CEO of VibroSense Dynamics, which is part of strengthening the organization with a focus on distributors and OEM customers.

Tarik Cengiz will work on developing existing partnerships in the company's current markets. He will also put a lot of focus on driving a geographic expansion and increased sales by addressing potential international partners such as distributors, agents or OEM partners.

VibroSense Dynamics AB has received a so-called "Intention To Grant" on its patent application in the EU, which strengthens the protection for the product VibroSense Meter® II. The patent describes a principle for measuring skin temperature wirelessly before and during an examination, which ensures measurement quality.

VibroSense Dynamics strengthens the organization by recruiting Tarik Cengiz as new CEO. Tarik will start his position as CEO on September 16, 2024 after he leaves his previous position as Global Sales Director at Arcoma AB.

Tarik Cengiz will work with developing existing partnerships in the company's current markets. He will also put a lot of focus on driving a geographic expansion and increased sales by addressing potential international partners such as distributors, agents or OEM partners.

The last and final step in obtaining regulatory approval of the VibroSense Meter ® II in China is delayed approximately four months. The delay is due to that VibroSense's Chinese distributor UMCARE has received many questions on its application, from the Chinese regulatory authority NMPA. According to UMCARE, the NMPA requires an extra careful review because there is no similar instrument in China, which is considered to be an advantage when the product is ready for launch in China.

VibroSense gains new momentum after the completion of the new share issue and increases investment in existing markets. At the same time, the company plans to gear up with more activities to reach out to new countries and thereby accelerate the company's sales.

VibroSense will mainly focus the use of the issue proceeds in the areas of sales and marketing, which is completely in line with what was communicated before the recently concluded new share issue.

Organization

VibroSense Dynamics AB (VibroSense) has got a patent approval in China. The patent describes a principle for measuring skin temperature wirelessly before and during an examination, which ensures measurement quality.

Obtaining the patent in China is part of a long-term strategy to protect VibroSense intellectual property rights. The patent protection will be further strengthened by several patent applications currently pending in various countries around the world. The current patent for wireless measurement of skin temperature was approved in Sweden in 2019.

VibroSense Chinese distributor UMCARE, announces that it has received a so-called "Notice of Acceptance" from the Chinese authority NMPA, regarding the company's application for regulatory approval in China for VibroSense Meter ® II and Diabetic Foot Screening.

The Diabetes Clinic at Steno Diabetes Center Odense, Denmark, has begun an evaluation of the VibroSense Meter® II with Diabetic Foot Screening as part of testing a new process to optimize patient flow.

Steno Diabetes Center, Odense has started a project to optimize patient flow as part of implementing a "One Stop Shop" concept, with the aim of minimizing the number of hospital visits for regular health checks of people living with diabetes.

The Diabetes Clinic, Skåne University Hospital in Lund has decided to introduce Diabetic Foot Screening as standard in the clinical operations, for regular control of nerve damage in the feet of people living with diabetes.

The diabetes clinic at Skåne University Hospital in Lund uses the VibroSense Meter® II and introduces the Diabetic Foot Screening examination as standard in its clinical operations. At the clinic, the methodology will be used in foot examinations of people living with diabetes.

In a publication on Plos One, the results of a clinical study were reported in which the company's technology Multi Frequency Vibrometry (MFV) was compared with Nerve Conduction Studies (NCS), which is generally regarded as the Gold Standard in the diagnosis of nerve damage caused by diabetes. The publication shows that there is a strong connection between MFV and NCS.